Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Citrus pectin, particularly in its modified form (Modified Citrus Pectin, MCP), has garnered scientific interest for its potential role in supporting inflammatory bowel disorders (IBD) such as Crohn's disease and ulcerative colitis. The rationale is based on pectin’s properties as a soluble dietary fiber, which can modulate the gut microbiota, promote the production of short-chain fatty acids (SCFAs), and improve intestinal barrier function. Preclinical studies in animal models have demonstrated that pectin supplementation can lead to reduced intestinal inflammation, decreased mucosal damage, and modulation of immune responses—possibly through the downregulation of pro-inflammatory cytokines and the upregulation of anti-inflammatory mediators. Some in vitro research suggests that citrus pectin may inhibit galectin-3, a protein implicated in inflammation and fibrosis. However, clinical evidence in humans remains limited. A handful of small pilot studies and case reports suggest some benefit in symptom management and inflammatory markers, but rigorous, large-scale randomized controlled trials are lacking. While the mechanistic plausibility and encouraging preclinical data justify further investigation, the overall quality and quantity of human evidence currently support only a modest role for citrus pectin in IBD management. It should not be considered a primary therapy but may be used as an adjunct under medical supervision.

More about citrus pectin
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by citrus pectin

Products containing citrus pectin